Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Swiss - Delayed Quote CHF

Curatis Holding AG (CURN.SW)

Compare

11.25

-0.65

(-5.46%)

At close: February 21 at 10:52:14 AM GMT+1

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

LIESTAL, Switzerland, November 14, 2024--Curatis Holding (SIX:CURN) has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years marke

Business Wire 3 months ago

CURN.SW
-5.46%
Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

LIESTAL, Switzerland, September 16, 2024--Curatis Holding (SIX:CURN) reports revenues of CHF 2.0m for H1 2024, whereby Curatis AG is only included for 2 months. Curatis AG was able to increase sales in the distribution business by 31% per cent to CHF 4.3m in the entire 6 months of 2024 compared to the first 6 months of 2023. The loss amounted to CHF 3.8m due to non-cash one-off effects and amortisation as well as transaction costs for the acquisition of Curatis AG. Cash flow, including one-time

Business Wire 5 months ago

CURN.SW
-5.46%
Curatis on track: submission of orphan drug designation application in the US for lead product candidate

LIESTAL, Switzerland, August 27, 2024--Curatis Holding (SIX:CURN) has submitted an orphan drug designation application to the US Food and Drug Administration (FDA) for its lead product candidate C-PBTE-01. The product is intended to alleviate the great suffering of children with side effects from a specific brain tumour.

Business Wire 5 months ago

CURN.SW
-5.46%

Performance Overview

Return	CURN.SW	MSCI WORLD
YTD	-13.46%	+3.34%
1-Year	-59.50%	+17.37%
3-Year	-96.49%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Curatis Holding AG (CURN.SW)

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Performance Overview